Surgery – Miscellaneous – Methods
Patent
1996-12-03
1999-06-08
Isabella, David J.
Surgery
Miscellaneous
Methods
514826, 514888, A61B 1900, A61K 704
Patent
active
059097345
ABSTRACT:
The use of leukotrienes and other products of the 5-lipoxygenase pathway to enhance bacterial defense and treat infections is described. The products are especially useful when administered to the lungs for the treatment of pneumonia and other lower respiratory tract infections. The products may be administered for treatment or prophylactic purposes and may be administered concomitantly with antibiotics to combat infection.
REFERENCES:
patent: 5145861 (1992-09-01), Ducep et al.
patent: 5674483 (1997-10-01), Tu et al.
M. Lohmann-Matthes et al., "Pulmonary Macrophages," Eur. Respir. J. 7:1678-1689 (1994).
J. Langermans et al., "Antimicrobial Functions of Mononuclear Phagocytes," J. Immunol. Methods 174:185-194 (1994).
S. Nelson et al., "Pathology of Pneunomia," Clin. Chest Med. 16(1):1-12 (1995).
E. Goetzl et al., "Specificity of Expression and Effects of Eicosanoid Mediators in Normal Physiology and Human Diseases," FASEB J 9:1051-1058 (1995).
J. Woods et al., "5-Lipoxygenase Is Located In the Euchromatin of the Nucleaus in Resting Human Alveolar Macrophages and Translocates to the Nuclear Envelope Upon Cell Activation," J. Clin. Invest. 95:2035-2040 (1995).
M. Peters-Golden et al., "Alterations In the Pattern of Arachidonate Metabolism Accompany Rat Macrophage Differentiation In the Lung," J. Immunol. 144(1):263-270 (1990).
T. Martin et al., Relative Contribution of Leukotriene B.sub.4 to the Neutrophil Chemotactic Activity Produced by the Resident Human Alveolar Macrophage, J. Clin. Invest. 80:1114-1124 (1989).
T. Martin et al., Effects of leukotriene B.sub.4 in the Human Lung. Recruitment of Neutrophils Into the Alveolar Spaces Without a Change in Protein Permeability, J. Clin. Invest. 84(5):1609-1619.
T. Demitsu et al., "Phagocytosis and Bactericidal Action of Mouse Peritoneal Macrophages Treated With Leukotriene B.sub.4," Int. J. Immunopharmac. 11(7):801-808 (1989).
P. Marder et al., "Blockade of Human Neutrophil Activation by xy!Benzioc Acid (LY293111), A Novel Leukotriene B.sub.4 Receptor Antagonist," Biochem. Pharmacol. 49(11):1683-1690 (1995).
C. Serhan et al., "Leukotriene B.sub.4 Is A Complete Secretagogue In Human Neutrophils: A Kinetic Analysis," Biochem. Biophys. Res. Commun. 107(3):1006-1012 (1982).
J. Wijkander et al., "5-Lipoxygenase Products Modulate the Activity of the 85-kDa Phospholipase A.sub.2 in Human Neutrophils," J. Biol. Chem. 270(44):26543-26549 (1995).
J. O'Flaherty et al., "Mechanisms Involved In the Bidirectional Effects of Protien Kinase C Activators on Neutrophil Responses to Leukotriene B.sub.4," J. Immunol. 144(5):1909-1913 (1990).
R. Strieter et al., "Cycotine-induced Neutrophil-derived Interlukin-8," Am. J. Pathol. 141(2):397-407 (1992).
R. Bray and Z. Brahmi, "Role of Lipoxygenation in Human Natural Killer Cell Activation," J. Immunol. 136(5):1783-1790 (1986).
J. Rhodes et al., "Macrophage Fc.gamma..sub.2b Receptor Expression and Receptor-Mediated Phospholipase Activity: Regulation By Endogenous Eicosanoids," Eur. J. Immunol. 15:222-227 (1985).
M. Peppelenbosch et al., "Epidermal Growth Factor-Induced Actin Remodeling Is Regulated by 5-Lipoxygenase and Cyclooxygenase Products," Cell 74:565-575 (1993).
A. Buret et al., Effector Mechanisms of Intestinally Induced Immunity To Pseudomonas Aeruginosa in the Rat Lung: Role of Neutrophils and Leukotriene B.sub.4, Infect. Immun. 61(2):671-679 (1993).
H. Hopkins et al., "Neutrophil Chemotactic Factors in Bacterial Pneumonia," Chest 95(5):1021-1027 (1989).
R. Moqbel et al., "Enhancement of Neutrophil- and Eosinophil-mediated Complement-dependent Killing of Schistosomula of Schistosoma Mansoni In Vitro By Leukotriene B.sub.4," Clin. Exp. Immunol. 52:519-527 (1983).
M. Balter et al., "Different Patterns of Arachidonate Metablism In Autologous Human Blood Monocytes and Alveolar Macrophages," J. Immunol. 142(2):602-608 (1989).
T.G. Brock et al., "Localization of 5-Lipoxygenase to the Nucleus of Unstimulated Rat Basophilic Leukemia Cells," J. Biol. Chem. 269(46):22059-22066 (1994).
M. Balter et al., "Multiple defects In Arachidonate Metabolism In Alveolar Macrophages From Young Asymptomatic Smokers," J. Lab.Clin. Med. 114:662-673 (1989).
M. Coffey et al., "5-Lipoxygenase Metabolism In Alveolar From Subjects Infected With thte Human Immunodeficiency Virus," J. Immunol. 157:393-399 (1996).
M.J. Coffey et al., "Reduced 5-Lipoxygenase Metabolism of Arachidonic Acid in Macrophages Rrom 1, 25-Dihydroxyvitamin D.sub.3 -Deficient Rats," Prostaglandins. 48:313-329 (1994).
J. Goulet et al., "Altered Inflammatory Responses In Leukotriene-Deficient Mice," Proc. Natl. Acad. Sci. USA 91:12852-12856 (1994).
X. Chen et al., "Role of Leukotrienes Revealed By Targeted Disruption of the 5-Lipoxygenase Gene," Nature 372:179-182 (1994).
McColm et al., "Evaluation of Ceftazidime In Experimental Klebsiela Pneumoniae Pneumonia: Comparison With Other Antibiotics qand Measurements of Its Penetration Into Respiratory Tissues and Secretions," J. Antimicrob. Chemother. 18:599-608 (1986).
M. Greenberger et al., "Neutralization of IL-10 Increases Survival In a Murine Model of Klebsiella Pneumonia," J. Immunol. 155:722-729 (1995).
M. Schneemann et al., "Nitric Oxide Synthase Is Not a Constituent of the Antimicrobial Armature of Human Mononuclear Phagocytes," J. Infect. Dis. 167:1358-1363 (1993).
J. Wilborn et al., "Constitutive Activation of 5-Lipoxygenase in the Lungs of Patients with Idiopathic Pulmonary Fibrosis," J. Clin. Invest. 97(8):1827-1836 (1996).
L. Laichalk et al., "Interleukin-10 Inhibits Neutrophil Phagocytic and Bactericidal Activity,"FEMS Immunol. Med. Microbiol. 658:1-7 (1996).
R. Crowell et al., "Hyperoxic Suppression of Fc-.gamma. Receptor-mediated Phagocytosis By Isolated Murine Pulmonary Macrophages," Am. J. Respir. Cell Mol. Biol. 12:190-195 (1995).
W. Hsueh et al., "LTB.sub.4 Production and Lysosomal Enzyme Release by Rat Alveolar Macrophages: Effects of Phagocytosis, Receptor Binding, and Ionophore Stimulation," Exp. Lung Res. 13:385-399 (1987).
G. Rosen et al., "Free Radicals and Phagocytic Cells,"FASEB J. 9:200-209 (1995).
N. Hubbard and K. Erickson, Role of 5'-Lipoxygenase Metabolites in the Activation of Peritoneal Macrophages for Tumoricidal Function, Mol. Immunol. 160:115-122 (1995).
N. Ahmed et al., "Transgenic Mice Expressing Rabbit C-Reactive Protein Exhibit Diminished Chemotatic Factor-Induced Alveolitis," Am. J. Respir. Crit. Care Med. 153:1141-1147 (1996).
W. Smith et al., "Characterization of 5-Lipoxygenase Inhibitors In Biochemical and Functional In Vivo Assays," J. Pharmacol. Exp. Ther. 275:1322-1338 (1995).
J. Drazen et al., Comparative Airway and Vascular Activities of Leukotrienes C-1 and In Vivo and In Vitro, Proc. Natl. Acad. Sci USA 77:4354-4358 (1980).
R. Harris et al., "Clinical Activity of Leukotriene Inhibitors," Int. J. Immunopharmac. 17(2):147-156 (1995.
R. Malaviya et al., "Reversible Translocation of 5-Lipoxygenase in Mast Cells Upon IgE," JBC 268(7):4939-4944 (1993).
I. Pavord et al., "Effect of Inhaled Prostaglandin E.sub.2 on Allergen-Induced Asthma," Am Rev Respir. Dis148:87-90 (1993).
M. Baile et al., "Leukotriene-Deficient Mice Manifest Enhanced Lethality from Klebsiella Pneumonia in Association with Decreased Alveolar Macrophage Phagocytic and Bactericidal Activities," The Journal of Immunology 157:5221-5224 (1996).
Peters-Golden Marc
Standiford Theodore
Isabella David J.
Regents of the University of Michigan
LandOfFree
Administration of products of the 5-lipoxygenase metabolic pathw does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Administration of products of the 5-lipoxygenase metabolic pathw, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Administration of products of the 5-lipoxygenase metabolic pathw will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1678726